Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 0

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 1
Chunk 0
---
Item
1. Interim Financial Statements.

DRUGS
MADE IN AMERICA ACQUISITION CORP.

BALANCE
SHEETS

(UNAUDITED)

    September
    30, 2025  
    December 31,
    2024 

    ASSETS 

    Current assets 

    Cash 
    $717  
    $1,351 
  
    Prepaid
    expenses and other current assets 
     27,479  
     3,640 
  
    Total
    Current Assets 
     28,196  
     4,991 

    Deferred
    offering costs 
     —  
     545,833 
  
    Cash
    and investments held in Trust Account 
     237,604,232  
     — 
  
    TOTAL
    ASSETS 
    $237,632,428  
    $550,824 

    LIABILITIES
    AND SHAREHOLDERS’ DEFICIT 

    Current
    liabilities 

    Accounts
    payable and accrued expenses 
    $302,623  
    $77,280 
  
    Accrued
    offering costs 
     153,988  
     56,065 
  
    Promissory
    note – related party 
     —  
     662,324 
  
    Total
    Current Liabilities 
     456,611  
     795,669 

    Deferred
    underwriting fee payable 
     6,900,000  
     — 
  
    Total
    Liabilities 
     7,356,611  
     795,669 

    Commitments 

    Ordinary shares subject to possible redemption, 23,000,000 shares at redemption value of $10.33 and $0 per share as of September 30, 2025 and December 31, 2024, respectively 
     237,604,232  
     — 

    Shareholders’
    Deficit 

    Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding as of September 30, 2025 and December 31, 2024 
     —  
     — 
  
    Ordinary shares, $0.0001 par value; 220,000,000 shares authorized; 10